1 Verve Therapeutics Disrupting the Care of Cardiovascular Disease Through Single-course Gene Editing Medicines January 2023 Forward looking statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the timing and availability of clinical data from the Company's heart-1 clinical trial, the timing of initiation of clinical trials of VERVE-201, th ...